Capturing immunotherapy response in a blood drop

byJohns Hopkins University School of MedicineAn impressionist painting of a liquid biopsy. Credit: Valsamo Anagnostou x DALL-E, openAILiquid biopsies are blood tests that can serially measure ci

Updated on: October 14,2023 296

Capturing immunotherapy response in a blood drop

byJohns Hopkins University School of MedicineAn impressionist painting of a liquid biopsy. Credit: Valsamo Anagnostou x DALL-E, openAILiquid biopsies are blood tests that can serially measure ci

Updated on:October 14,2023 296

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on: October 12,2023 176

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on:October 12,2023 176

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on: October 12,2023 185

MDNA11 Generates Activity, Safety in Advanced Solid Tumors

August 9, 2023Chris RyanTreatment with the long-acting interleukin-2 superkine led to durable tumor control and no dose-limiting toxicities in patients with advanced solid tumors, according to data fr

Updated on:October 12,2023 185

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on: October 12,2023 26

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on:October 12,2023 26

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on: October 12,2023 261

Frontline Immunotherapy, Delayed Nephrectomy May Allow for Improved Disease Control in mRCC

July 14, 2023Caroline SeymourNeoadjuvant immunotherapy–based combinations led to reductions in tumor size and pathologic necrosis at the time of cytoreductive nephrectomy in patients with metastatic r

Updated on:October 12,2023 261

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on: October 12,2023 41

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on:October 12,2023 41

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023 131

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023 131

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023 6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023 6

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023 202

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023 202

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on: October 12,2023 22

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on:October 12,2023 22

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

Neurosurgery: new augmented reality technology helps to complete multiple surgeries

Augmented reality accurate localization, assisting endoscopic cerebral hematoma removal surgeryThe Department of Neurosurgery (Digital/Secure Neurosurgery) of the East Campus accurately localized a

Updated on: October 12,2023 267

Neurosurgery: new augmented reality technology helps to complete multiple surgeries

Augmented reality accurate localization, assisting endoscopic cerebral hematoma removal surgeryThe Department of Neurosurgery (Digital/Secure Neurosurgery) of the East Campus accurately localized a

Updated on:October 12,2023 267